Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trial
Background CheckMate 9KD (NCT03338790) is a non-randomized, multicohort, phase 2 trial of nivolumab plus other anticancer treatments for metastatic castration-resistant prostate cancer (mCRPC). We report results from cohorts A1 and A2 of CheckMate 9KD, specifically evaluating nivolumab plus rucapari...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
17 August 2022
|
| In: |
Journal for ImmunoTherapy of Cancer
Year: 2022, Jahrgang: 10, Heft: 8, Pages: 1-14 |
| ISSN: | 2051-1426 |
| DOI: | 10.1136/jitc-2022-004761 |
| Online-Zugang: | Verlag, kostenfrei, Volltext: https://doi.org/10.1136/jitc-2022-004761 Verlag, kostenfrei, Volltext: https://jitc.bmj.com/content/10/8/e004761 
|
| Verfasserangaben: | Karim Fizazi, Margitta Retz, Daniel P. Petrylak, Jeffrey C. Goh, Jose Perez-Gracia, Louis Lacombe, Stefanie Zschäbitz, Mauricio Burotto, Hakim Mahammedi, Gwenaelle Gravis, Diogo Assed Bastos, Steven L. McCune, Juan Carlos Vázquez Limón, Edmond M. Kwan, Daniel Castellano, Aude Fléchon, Fred Saad, Marc-Oliver Grimm, David R. Shaffer, Andrew J. Armstrong, Prabhu Bhagavatheeswaran, Neha P. Amin, Keziban Ünsal-Kaçmaz, Xuya Wang, Jun Li, Andrea Loehr, Russell K. Pachynski |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1823191002 | ||
| 003 | DE-627 | ||
| 005 | 20230426190838.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 221122s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1136/jitc-2022-004761 |2 doi | |
| 035 | |a (DE-627)1823191002 | ||
| 035 | |a (DE-599)KXP1823191002 | ||
| 035 | |a (OCoLC)1361692129 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Fizazi, Karim |e VerfasserIn |0 (DE-588)138277079 |0 (DE-627)601096843 |0 (DE-576)306985349 |4 aut | |
| 245 | 1 | 0 | |a Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer |b results from the phase 2 CheckMate 9KD trial |c Karim Fizazi, Margitta Retz, Daniel P. Petrylak, Jeffrey C. Goh, Jose Perez-Gracia, Louis Lacombe, Stefanie Zschäbitz, Mauricio Burotto, Hakim Mahammedi, Gwenaelle Gravis, Diogo Assed Bastos, Steven L. McCune, Juan Carlos Vázquez Limón, Edmond M. Kwan, Daniel Castellano, Aude Fléchon, Fred Saad, Marc-Oliver Grimm, David R. Shaffer, Andrew J. Armstrong, Prabhu Bhagavatheeswaran, Neha P. Amin, Keziban Ünsal-Kaçmaz, Xuya Wang, Jun Li, Andrea Loehr, Russell K. Pachynski |
| 264 | 1 | |c 17 August 2022 | |
| 300 | |a 14 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 22.11.2022 | ||
| 520 | |a Background CheckMate 9KD (NCT03338790) is a non-randomized, multicohort, phase 2 trial of nivolumab plus other anticancer treatments for metastatic castration-resistant prostate cancer (mCRPC). We report results from cohorts A1 and A2 of CheckMate 9KD, specifically evaluating nivolumab plus rucaparib. | ||
| 650 | 4 | |a Immunotherapy | |
| 700 | 1 | |a Retz, Margitta |e VerfasserIn |4 aut | |
| 700 | 1 | |a Petrylak, Daniel P. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Goh, Jeffrey C. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Perez-Gracia, Jose |e VerfasserIn |4 aut | |
| 700 | 1 | |a Lacombe, Louis |e VerfasserIn |4 aut | |
| 700 | 1 | |a Zschäbitz, Stefanie |d 1983- |e VerfasserIn |0 (DE-588)1037698827 |0 (DE-627)75589894X |0 (DE-576)391727206 |4 aut | |
| 700 | 1 | |a Burotto, Mauricio |e VerfasserIn |4 aut | |
| 700 | 1 | |a Mahammedi, Hakim |e VerfasserIn |4 aut | |
| 700 | 1 | |a Gravis, Gwenaelle |e VerfasserIn |4 aut | |
| 700 | 1 | |a Bastos, Diogo Assed |e VerfasserIn |4 aut | |
| 700 | 1 | |a McCune, Steven L. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Limón, Juan Carlos Vázquez |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kwan, Edmond M. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Castellano, Daniel |e VerfasserIn |4 aut | |
| 700 | 1 | |a Fléchon, Aude |e VerfasserIn |4 aut | |
| 700 | 1 | |a Saad, Fred |e VerfasserIn |4 aut | |
| 700 | 1 | |a Grimm, Marc-Oliver |e VerfasserIn |4 aut | |
| 700 | 1 | |a Shaffer, David R. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Armstrong, Andrew J. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Bhagavatheeswaran, Prabhu |e VerfasserIn |4 aut | |
| 700 | 1 | |a Amin, Neha P. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Ünsal-Kaçmaz, Keziban |e VerfasserIn |4 aut | |
| 700 | 1 | |a Wang, Xuya |e VerfasserIn |4 aut | |
| 700 | 1 | |a Li, Jun |e VerfasserIn |4 aut | |
| 700 | 1 | |a Loehr, Andrea |e VerfasserIn |4 aut | |
| 700 | 1 | |a Pachynski, Russell K. |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal for ImmunoTherapy of Cancer |d London : BioMed Central, 2013 |g 10(2022), 8, Artikel-ID e004761, Seite 1-14 |h Online-Ressource |w (DE-627)750086335 |w (DE-600)2719863-7 |w (DE-576)383767369 |x 2051-1426 |7 nnas |a Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer results from the phase 2 CheckMate 9KD trial |
| 773 | 1 | 8 | |g volume:10 |g year:2022 |g number:8 |g elocationid:e004761 |g pages:1-14 |g extent:14 |a Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer results from the phase 2 CheckMate 9KD trial |
| 856 | 4 | 0 | |u https://doi.org/10.1136/jitc-2022-004761 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u https://jitc.bmj.com/content/10/8/e004761 |x Verlag |z kostenfrei |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20221122 | ||
| 993 | |a Article | ||
| 994 | |a 2022 | ||
| 998 | |g 1037698827 |a Zschäbitz, Stefanie |m 1037698827:Zschäbitz, Stefanie |d 910000 |d 910100 |e 910000PZ1037698827 |e 910100PZ1037698827 |k 0/910000/ |k 1/910000/910100/ |p 7 | ||
| 999 | |a KXP-PPN1823191002 |e 4218267650 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"language":["eng"],"person":[{"display":"Fizazi, Karim","family":"Fizazi","role":"aut","given":"Karim"},{"family":"Retz","display":"Retz, Margitta","role":"aut","given":"Margitta"},{"display":"Petrylak, Daniel P.","family":"Petrylak","given":"Daniel P.","role":"aut"},{"family":"Goh","display":"Goh, Jeffrey C.","given":"Jeffrey C.","role":"aut"},{"family":"Perez-Gracia","display":"Perez-Gracia, Jose","role":"aut","given":"Jose"},{"given":"Louis","role":"aut","family":"Lacombe","display":"Lacombe, Louis"},{"given":"Stefanie","role":"aut","display":"Zschäbitz, Stefanie","family":"Zschäbitz"},{"display":"Burotto, Mauricio","family":"Burotto","role":"aut","given":"Mauricio"},{"role":"aut","given":"Hakim","family":"Mahammedi","display":"Mahammedi, Hakim"},{"given":"Gwenaelle","role":"aut","family":"Gravis","display":"Gravis, Gwenaelle"},{"family":"Bastos","display":"Bastos, Diogo Assed","given":"Diogo Assed","role":"aut"},{"family":"McCune","display":"McCune, Steven L.","role":"aut","given":"Steven L."},{"family":"Limón","display":"Limón, Juan Carlos Vázquez","role":"aut","given":"Juan Carlos Vázquez"},{"display":"Kwan, Edmond M.","family":"Kwan","given":"Edmond M.","role":"aut"},{"family":"Castellano","display":"Castellano, Daniel","given":"Daniel","role":"aut"},{"role":"aut","given":"Aude","display":"Fléchon, Aude","family":"Fléchon"},{"display":"Saad, Fred","family":"Saad","given":"Fred","role":"aut"},{"given":"Marc-Oliver","role":"aut","family":"Grimm","display":"Grimm, Marc-Oliver"},{"role":"aut","given":"David R.","display":"Shaffer, David R.","family":"Shaffer"},{"given":"Andrew J.","role":"aut","display":"Armstrong, Andrew J.","family":"Armstrong"},{"display":"Bhagavatheeswaran, Prabhu","family":"Bhagavatheeswaran","role":"aut","given":"Prabhu"},{"given":"Neha P.","role":"aut","display":"Amin, Neha P.","family":"Amin"},{"family":"Ünsal-Kaçmaz","display":"Ünsal-Kaçmaz, Keziban","given":"Keziban","role":"aut"},{"given":"Xuya","role":"aut","display":"Wang, Xuya","family":"Wang"},{"display":"Li, Jun","family":"Li","given":"Jun","role":"aut"},{"display":"Loehr, Andrea","family":"Loehr","given":"Andrea","role":"aut"},{"family":"Pachynski","display":"Pachynski, Russell K.","role":"aut","given":"Russell K."}],"id":{"eki":["1823191002"],"doi":["10.1136/jitc-2022-004761"]},"physDesc":[{"extent":"14 S."}],"name":{"displayForm":["Karim Fizazi, Margitta Retz, Daniel P. Petrylak, Jeffrey C. Goh, Jose Perez-Gracia, Louis Lacombe, Stefanie Zschäbitz, Mauricio Burotto, Hakim Mahammedi, Gwenaelle Gravis, Diogo Assed Bastos, Steven L. McCune, Juan Carlos Vázquez Limón, Edmond M. Kwan, Daniel Castellano, Aude Fléchon, Fred Saad, Marc-Oliver Grimm, David R. Shaffer, Andrew J. Armstrong, Prabhu Bhagavatheeswaran, Neha P. Amin, Keziban Ünsal-Kaçmaz, Xuya Wang, Jun Li, Andrea Loehr, Russell K. Pachynski"]},"relHost":[{"id":{"zdb":["2719863-7"],"issn":["2051-1426"],"eki":["750086335"]},"recId":"750086335","physDesc":[{"extent":"Online-Ressource"}],"type":{"bibl":"periodical","media":"Online-Ressource"},"disp":"Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer results from the phase 2 CheckMate 9KD trialJournal for ImmunoTherapy of Cancer","title":[{"title":"Journal for ImmunoTherapy of Cancer","title_sort":"Journal for ImmunoTherapy of Cancer","subtitle":"official journal of the Society for Immunotherapy of Cancer (SITC)"}],"origin":[{"dateIssuedDisp":"2013-","dateIssuedKey":"2013","publisher":"BioMed Central","publisherPlace":"London"}],"note":["Gesehen am 29.06.20"],"pubHistory":["1.2013 -"],"part":{"year":"2022","pages":"1-14","issue":"8","text":"10(2022), 8, Artikel-ID e004761, Seite 1-14","volume":"10","extent":"14"},"language":["eng"]}],"recId":"1823191002","type":{"media":"Online-Ressource","bibl":"article-journal"},"title":[{"subtitle":"results from the phase 2 CheckMate 9KD trial","title_sort":"Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer","title":"Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer"}],"note":["Gesehen am 22.11.2022"],"origin":[{"dateIssuedKey":"2022","dateIssuedDisp":"17 August 2022"}]} | ||
| SRT | |a FIZAZIKARINIVOLUMABP1720 | ||